Abstrak
Glimepiride is the latest second-generation sulphonylurea antihyperglycemic agent for oral therapy of type-2 diabetes mellitus. Its main action is stimulating insulin release from pancreatic β-cells.
1,2 Glimepiride binds to a 65 kD submit of sulfonylurea receptor (SUR1) that forms a complex with an ATP-sensitive potassium channel called KIR 6.2 that is embedded in the pancreatic β-cell plasma membrane. Binding of the ligand sulfonylurea to SUR1 closes the KIR channel, resulting in membrane depolarization, which opens voltage-dependent calcium channels and leads to calcium influx into the cell.
1,2 The elevated intracellular calcium levels trigger insulin secretion. It is a direct insulin secretagogue action; indirectly, it also increases insulin secretion in response to fuels such as glucose.
2
In comparison to glibenclamide, glimepiride produces less marked hyperinsulinemia, causing a lower risk of hypoglycemia.
2 Glimepiride enhances both the firstphase and the second-phase of insulin secretion.
3
Glimepiride also has extrapancreatic actions. It improves the insulin sensitivity of peripheral tissues by increasing the number of glucose transporter molecules (GLUT1 and GLUT4) in the plasma membrane of muscle and adipose tissues and enhances their glucose uptake. [1] [2] [3] [4] Glimepiride significantly improved insulin resistance, suggested by a significant reduction of HOMA-IR (homeostasis model assessment of insulin resistance). 5, 6 Increased plasma adiponectin and decreased plasma TNF-α may underline the improvement of insulin resistance with glimepiride. 5, 6 Glimepiride also activates glycogenesis and lipogenesis, and inhibits hepatic gluconeogenesis. 1, 2, 4 Both pancreatic (the increase in insulin secretion) and extrapancreatic (the improvement of glucose utilization) actions are responsible for the glucose-lowering properties of glimepiride. [1] [2] [3] [4] After oral administration, glimepiride is completely absorbed, reaching peak plasma concentration at 2.4 to 3.8 hours in patients with type-2 diabetes. The terminal elimination half-life of 1 to 8 mg doses was 3.2 to 8.8 hours.
1
The usual initial dose is 1 mg once daily. If necessary, based on regular blood sugar monitoring, the daily dose can be increased gradually at intervals of 1-2 weeks, and carried out stepwise to 2 mg-3mg-4mg, and in exceptional cases, 8 mg. The dose should be taken immediately before a substantial breakfast or, if none is taken, immediately before the first main meal. It is very important not to skip meals after taking glimepiride. 7 This convenient once daily dosing may enhance compliance for diabetic patients who often also require medications for other co-morbid conditions.
2
In comparison studies with equieffective doses of glibenclamide, glimepiride caused a lower incidence of hypoglycemia. 8, 9 The primary objective of the present observational study was to evaluate glimepiride monotherapy in controlling blood glucose in patients with type-2 diabetes by examining HbA 1c value. The other objectives were to evaluate the average glimepiride dosage used to achieve good blood glucose control, and to assess glimepiride safety profile and also patients' compliance.
PATIENTS AND METHODS

Patients
Male and female patients, aged 20 years or older, with type-2 diabetes mellitus, HbA 1c more than 7%, and received no oral antidiabetic treatment for the last 3 months or longer (treatment naive or previously treated) were eligible for the study. Patients with hypersensitivity to glimepiride or other sulfonylureas or other sulfonamides or any of the excipients of glimepiride tablet, pregnant women, nursing mothers, or women of childbearing potential without a reliable contraceptive measure, including postmenopausal women for less than 2 years, were excluded from the study. Patients participating in another investigational study were also excluded.
Study design and procedure
This was a prospective, observational study of patients with type-2 diabetes mellitus receiving glimepiride monotherapy for 3 months. The study was carried out at 4 private clinics in Semarang, Jambi, Mojokerto and Medan between 18 October 2006 and 29 September 2007.
Amaryl
® (glimepiride) was given once daily immediately before a substantial breakfast or the first main meal. The starting dose and the dose titration were decided by the physician based on patient's fasting blood glucose value (using glucometer at the physician office). The maximum permitted daily dose was 6 mg. The laboratory HbA 1c examination was done twice, at baseline and at the end of this 3 months study. There were 4 mandatory visits at month 0 (baseline visit, V1), 1 month (V2), 2 months (V3) and 3 months (end of study, V4). The in-between scheduled visits up to 3 months were arranged as necessary. 
Assessments
The primary efficacy variables in the present study were the changes of HbA 1c and fasting blood glucose (FBG) values from baseline at the end of 3 months treatment. The other variables to be assessed were the initial and the final doses of glimepiride of the naive patients and of the previously treated patients, and also the decreased in HbA 1c and FBG in those 2 groups of patients. The effects of BMI (normal, overweight, and obese) were also evaluated on the decrease in HbA 1c , FBG, and body weight .
At the end of 3 months treatment, the percentages of patients reaching the target of HbA 1c (<7%) and of FBG (<120mg/dL) were calculated and the reasons for not reaching the target were evaluated. The average glimepiride dose used and patients' compliance for taking glimepiride monotherapy were also evaluated.
The safety profile of glimepiride monotherapy was assessed in all patients taking this drug, even only 1 tablet, as long as he/she had at least once postbaseline visit.
Data analyses
Demographics and baseline characteristics were presented for all patients. Patients were then divided into 2 subgroups, the treatment naive patients and the previously treated patients. For both subgroups, the decrease in HbA 1c and FBG were calculated, and also the initial and final doses of glimepiride. Then the patients were divided into 3 subgroups based on the BMI (the normal, the overweight, and the obese), and in each subgroup, the decrease in HbA 1c , FBG and body weight were calculated. Lastly, the proportion of patients reaching target HbA 1c (<7%) and those reaching target FBG (<120 mg/dL) were calculated, and also patients' compliance was evaluated. All analyses were descriptive statistics.
Adverse events, considered related or unrelated by the physicians, were listed with their respective incidences.
RESULTS
Patients
A total of 74 patients were eligible for the study and received glimepiride at baseline visit. Eighteen patients were lost to follow-up at visits 2, 3, and 4 (13, 2, and 3 patients, respectively), leaving 56 patients who completed this 3 months study and who were therefore evaluable for efficacy. No adverse events were noted for those patients who were lost to follow-up. The demographics and baseline characteristics of the 56 patients are presented in Table 1. normal, the overweight, and the obese), and in each subgroup, the decrease in HbA 1c, FBG and body weight were calculated. Lastly, the proportion of patients reaching target HbA 1c (<7%) and those reaching target FBG (<120 mg/dL) were calculated, and also patients' compliance was evaluated. All analyses were descriptive statistics.
RESULTS
Patients
A total of 74 patients were eligible for the study and received glimepiride at baseline visit.
Eighteen patients were lost to follow-up at visits 2, 3, and 4 (13, 2, and 3 patients, respectively), leaving 56 patients who completed this 3 months study and who were therefore evaluable for efficacy. No adverse events were noted for those patients who were lost to follow-up. The demographics and baseline characteristics of the 56 patients are presented in Table 1 . and those reaching target FBG (<120 mg/dL) were calculated, and also patients' compliance was evaluated. All analyses were descriptive statistics.
RESULTS
Patients
Eighteen patients were lost to follow-up at visits 2, 3, and 4 (13, 2, and 3 patients, respectively), leaving 56 patients who completed this 3 months study and who were therefore evaluable for efficacy. No adverse events were noted for those patients who were lost to follow-up. The demographics and baseline characteristics of the 56 patients are presented in Table 1 . There was a slightly higher prevalence of male than female patients (54% vs 46%), while the mean age of all patients was 53.0 years. The mean HbA 1c was 10.4%, the mean FBG was 224 mg/dL, and the mean BMI was 24 kg/m2 at baseline. The mean BP was 128/80 mm Hg at baseline (Table 1) . The mean BMI, HbA 1c , and FBG were higher in treatment-naïve patients than in previously treated patients (Table 1) . The newly diagnosed patients were 26 (46%). Most of the previously (> 3 months) treated patients received sulfonylureas (96.7%), and glibenclamide was the most common sulfonylureas prescribed (62.1%) ( Table 3 ). The newly diagnosed patients were 26 (46%). Most of the previously (>3 months) treated patients received sulfonylureas (96.7%), and glibenclamide was the most common sulfonylureas prescribed (62.1%) ( Table 3) . The newly diagnosed patients were 26 (46%). Most of the previously (> 3 months) treated patients received sulfonylureas (96.7%), and glibenclamide was the most common sulfonylureas prescribed (62.1%) ( Table 3) . The newly diagnosed patients were 26 (46%). Most of the previously (> 3 months) treated patients received sulfonylureas (96.7%), and glibenclamide was the most common sulfonylureas prescribed (62.1%) ( Table 3) . The mean initial glimepiride dose for all patients was 2.0 mg daily, which increased to 2.3 mg daily, the final dose (at 3 months). The mean initial doses for naive patients and previously treated patients were similar, i.e. 2.0 mg daily. The mean final doses were also similar, i.e. 2.3 mg daily (Table 4) .
For all patients, the mean (SD) decrease in HbA 1c after 3 months treatment was 1.8 (2.3%). In naive patients, the decrease was 2.3%, while in previously treated patients, it was 1.3%. According to initial BMI, the mean (SD) decrease of HbA1c in normal weight patients was 1.3 (2.5%), but the decrease in obese patients was 2.4% ( Table 5 ).
The mean initial glimepiride dose for all patients was 2.0 mg daily, which increased to 2.3 mg daily, the final dose (at 3 months). The mean initial doses for naive patients and previously treated patients were similar, i.e. 2.0 mg daily. The mean final doses were also similar, i.e. 2.3 mg daily (Table 4 ). For all patients, the mean (SD) decrease in HbA 1c after 3 months treatment was 1.8 (2.3%). In naive patients, the decrease was 2.3%, while in previously treated patients, it was 1.3%.
According to initial BMI, the mean (SD) decrease of HbA 1c in normal weight patients was 1.3 (2.5%), but the decrease in obese patients was 2.4% (Table 5 ). The mean initial glimepiride dose for all patients was 2.0 mg daily, which increased to 2.3 mg daily, the final dose (at 3 months). The mean initial doses for naive patients and previously treated patients were similar, i.e. 2.0 mg daily. The mean final doses were also similar, i.e. 2.3 mg daily (Table 4) . For all patients, the mean (SD) decrease in HbA 1c after 3 months treatment was 1.8 (2.3%). In naive patients, the decrease was 2.3%, while in previously treated patients, it was 1.3%.
According to initial BMI, the mean (SD) decrease of HbA 1c in normal weight patients was 1.3 (2.5%), but the decrease in obese patients was 2.4% (Table 5 ). The mean (SD) decline in FBG after 3 months treatment for all patients was 54 (83) mg/dL. For naive patients, the decrease was 83 mg/dL, and in previously treated patients, it was 30 mg/dL. Based on the initial BMI, the mean (SD) decline of FBG in normal weight patients was 59 (79) mg/ dL, and in obese patients the decline was similar, i.e. 60 mg/dL (Table 6 ).
After 3 months of therapy, the body weight of patients increased with a mean (SD) of 0.9 (2.2) kg (Table 7) . Table 5 . HbA1c (%) in patients with type-2 DM who completed the study (n=56) Figure 1 . Mean HbA1c change in treatment-naive and previously treated patients, and in normal and obese patients. The mean (SD) decline in FBG after 3 months treatment for all patients was 54 (83) mg/dL. For naive patients, the decrease was 83 mg/dL, and in previously treated patients, it was 30 mg/dL.
Based on the initial BMI, the mean (SD) decline of FBG in normal weight patients was 59 (79) mg/dL, and in obese patients the decline was similar, i.e. 60 mg/dL (Table 6 ). After 3 months of therapy, the body weight of patients increased with a mean (SD) of 0.9 (2.2) kg (Table 7) . The mean (SD) decline in FBG after 3 months treatment for all patients was 54 (83) mg/dL. For naive patients, the decrease was 83 mg/dL, and in previously treated patients, it was 30 mg/dL.
Based on the initial BMI, the mean (SD) decline of FBG in normal weight patients was 59 (79) mg/dL, and in obese patients the decline was similar, i.e. 60 mg/dL (Table 6 ). (Table 7) . The mean (SD) decline in FBG after 3 months treatment for all patients was 54 (83) mg/dL. For naive patients, the decrease was 83 mg/dL, and in previously treated patients, it was 30 mg/dL.
Based on the initial BMI, the mean (SD) decline of FBG in normal weight patients was 59 (79) mg/dL, and in obese patients the decline was similar, i.e. 60 mg/dL (Table 6 ). Table 7 . Body weight (kg) in patients with type-2 DM who completed the study (n=56) After 3 months of therapy, the body weight of patients increased with a mean (SD) of 0.9 (2.2) kg (Table 7) . Table 8) .
Patients reaching the target FBG after 3 months of therapy were 10 patients among a total of 56 patients (18%), consisting of 6 patients among 26 treatment-naive patients (23%) and 4 patients among 30 previously treated patients (13.3%) ( Table 9 ).
The mean (range) initial glimepiride dose for patients reaching target HbA 1c was 2.1 (1-3) mg daily and the final dose was 2.0 (1-3) mg daily, while for patients not reaching target HbA1c the initial glimepiride dose was 2.0 (1-3) mg daily and the final dose was 2.4 (1-4) mg/day.
Reasons for not reaching the HbA1c and FBG target at the end of study (3 months The predominant reason for not reaching the target blood glucose was poor diabetic education (in 31 patients or 55% of all patients)
The mean systolic blood pressure decreased by 3.4 mm Hg and mean diastolic blood pressure by 0.7 mm Hg.
No adverse event, including hypoglycemia, was encountered during 3 months monotherapy with glimepiride in the present study. Discontinuation rate was 18 patients from 74 patients originally enrolled in the present study. These 18 patients were all lost to follow up without any explanation noted in the case report forms. No AEs were reported for these 18 patients. Table 8) .
Patients reaching the target FBG after 3 months of therapy were 10 patients among a total of 56 patients (18%), consisting of 6 patients among 26 treatment-naive patients (23%) and 4 patients among 30 previously treated patients (13.3%) ( Table 9 ). The mean (range) initial glimepiride dose for patients reaching target HbA 1c was 2.1 (1-3) mg daily and the final dose was 2.0 (1-3) mg daily, while for patients not reaching target HbA 1c the initial glimepiride dose was 2.0 (1-3) mg daily and the final dose was 2.4 (1-4) mg/day.
Reasons for not reaching the HbA and FBG target at the end of study (3 months) were: Table 8) .
Patients reaching the target FBG after 3 months of therapy were 10 patients among a total of 56 patients (18%), consisting of 6 patients among 26 treatment-naive patients (23%) and 4 patients among 30 previously treated patients (13.3%) ( Table 9 ). No adverse event, including hypoglycemia, was encountered during 3 months monotherapy with glimepiride in the present study. Discontinuation rate was 18 patients from 74 patients originally enrolled in the present study. These 18 patients were all lost to follow up without any Table 9 . Patients reaching the target FBG (< 120 mg/dL) among all patients with type-2 DM who completed the study (n=56) 
DISCUSSION
After 3 months of therapy, the mean decrease in HbA 1c levels was 1.8% for all patients, higher in naive patients (2.3%) than in previously treated patients (1.3%). These results were consistent with the results of Scholz et al. in more than 22.000 patients with type-2 DM. 4 However, the variation was large, in some patients (17.9%) the HbA 1c levels were actually increased. These increased HbA 1c levels were found in 4 naive patients (15.4%), and in 6 previously treated patients (20%).
Based on initial BMI, the mean decrease in HbA 1c levels was 1.3% for normal weight patients, and 2.4% for obese patients. These results were also consistent with the findings of Scholz et al. 4 For overweight patients, the mean decrease was only 0.9%, it may be due to the small sample (only 10 patients).
The doses of glimepiride were not different in treatmentnaive patients and in previously treated patients, either the initial dose (2.0 mg) or the final dose (2.3%).
The mean decrease in FBG levels after 3 months of therapy was 54 mg/dL for all patients, and higher in naive patients (83 mg/dL) than in previously treated patients (30 mg/dL). Again, the variation was large, with some patients had increased FBG levels. The increased FBG levels were detected in 11 patients among the whole group of patients (19.6%), in 5 naive patients (19.2%), and in 6 previously treated patients (20%).
The initial BMI had no effect on the mean decrease of FBG levels, which was 59 mg/dL in normal weight patients and 60 mg/dL in obese patients.
Treatment with insulin or insulin secretagogue is often associated with weight gain. Glimepiride, however, has been associated with weight neutrality or even weight loss in a number of trials.
4
In the present study, a mean weight gain of 0.9 kg for all patients (n= 50) was noted. These results suggested that glimepiride, just like other insulin secretagogue, was associated with weight gain, although in the present study, due to the large variation, the increase in body weight was not statistically significant.
In the present study, after 3 months of therapy, glimepiride monotherapy achieved target HbA 1c (< 7%) in 12 patients from a total of 56 patients (21.4%). In 26 naive patients, 5 patients reached target HbA 1c (19.2%), while in 30 previously treated patients, 7 patients reached target HbA 1c (23.3%). The target FBG (< 120 mg/dL) was reached by 10 patients among the total of 56 patients receiving glimepiride monotherapy for 3 months (18%). In 26 naive patients, 6 patients reached the target FBG (23%), and in 30 previously treated patients, 4 patients reached target FBG (13.3%). This low rate in achieving the target HbA 1c and FBG in present study may be due to the short duration of study (3 months), high baseline values, and lack of dose escalation. Although the percentage of patients reaching target FBG was unexpectedly small (only 18%), but the proportion of success in treatment-naive patients and in previously treated patients was as expected. On the contrary, the proportion of reaching target HbA 1c in treatmentnaive patients and in previously treated patients was unexpected, also among patients with baseline HbA 1c 7-10%, which may be due to chance, considering the small number of patients. In the present study, the dose escalation was only until 4 mg in some patients due to the investigators' fear of hypoglycemia considering the short duration of study (only 3 months) although no hypoglycemia was reported during the study.
There were various reasons for not reaching the target blood glucose, but the predominant reason was poor diabetic education (in 55% of all patients). There may be some correlation between this poor diabetic education with the poor formal education received by most of our subjects. The major contribution, however, rested with the treating physicians, who did not spend enough time to explain the hazards of having poor diabetic control, due to resource constraint. "Dosage not optimum" was reported for 34% of the patients. The mean dose of Glimepiride at the end of the study was relatively low at 2.4mg for patients who had not achieved target HbA1c, with room for further dose escalation.
As expected, patients who reached good diabetic control (reached target HbA 1c ) also had good compliance in taking glimepiride. Around 90% of these patients showed >90% compliance in taking glimepiride every month during this 3 months of therapy. Only around 70% of patients who did not achieve good blood glucose control showed >90% compliance in taking glimepiride.
There was no adverse event found during this 3 months monotherapy with glimepiride. There were 18 patients lost to follow-up, but there was no explanation of the reason in the case report forms. Hypoglycemia, the mostly reported adverse reaction after glimepiride, was not reported in the present study. It may due to the low dose used in this study, in which the highest dose was
